In short
This article explores the use of autologous T-cells transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) directed against CD19 in clinical trials. This innovative therapy, known as CAR T-cell therapy, is being investigated for various conditions, including relapsed or refractory B-cell malignancies and certain autoimmune diseases. The trials aim to assess the safety, efficacy, and feasibility of this personalized treatment approach in patients who have not responded well to conventional therapies.
At a glance
- Therapy Name
- MB-CART19.1 (CD19 CAR transduced T cells)
- Type of Therapy
- Autologous CAR T-cell therapy
- Target
- CD19 protein on B-cells
- Conditions Studied
- Relapsed/refractory B-cell malignancies (ALL, NHL, CLL), Systemic Lupus Erythematosus, Systemic Sclerosis, Dermatomyositis/Polymyositis
- Administration
- Intravenous infusion
- Trial Phases
- Phase I/II
- Primary Objectives
- Safety assessment, dose determination, efficacy evaluation
- Key Endpoints
- Incidence of adverse events, overall response rate, CAR T-cell persistence
- Potential Side Effects
- Cytokine Release Syndrome, Neurotoxicity, B-cell depletion, Infections
- Patient Eligibility
- Varies by trial; generally includes refractory/relapsed status, specific disease criteria, adequate organ function
Overview
AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CD19, also known as MB-CART19.1 or CD19-CAR_Lenti, is an innovative cell therapy being investigated for the treatment of various conditions. This therapy belongs to a class of treatments called CAR T-cell therapy, which harnesses the power of a patient's own immune system to fight diseases.
Mechanism of Action
The treatment involves taking T-cells (a type of immune cell) from the patient's own body and genetically modifying them in a laboratory. These modified T-cells are equipped with a special receptor called a chimeric antigen receptor (CAR) that targets CD19, a protein found on the surface of certain cells.
The process involves the following steps:
- T-cells are collected from the patient's blood through a process called leukapheresis.
- The T-cells are genetically modified using a lentiviral vector, which introduces the CAR gene into the cells.
- The modified T-cells are grown and multiplied in the laboratory.
- The patient receives chemotherapy to prepare their body for the treatment.
- The modified CAR T-cells are infused back into the patient's body.
Once in the body, these CAR T-cells can recognize and attack cells that express CD19, potentially eliminating diseased cells while sparing healthy ones.
Conditions Treated
MB-CART19.1 is being investigated for the treatment of several conditions, including:
- B-cell malignancies: This includes various types of blood cancers such as:
- Acute Lymphoblastic Leukemia (ALL)
- Non-Hodgkin's Lymphoma (NHL)
- Chronic Lymphocytic Leukemia (CLL)
- Acute Myeloid Leukemia (AML) expressing CD19
- Autoimmune diseases: The therapy is also being explored for treating certain autoimmune conditions, including:
- Systemic Lupus Erythematosus (SLE)
- Systemic Sclerosis (SSc)
- Dermatomyositis/Polymyositis (DM/PM)
These conditions are typically treated when they are refractory (resistant to standard treatments) or relapsed (have returned after initial treatment).
Administration
MB-CART19.1 is administered as an intravenous infusion. Before the infusion, patients typically receive a conditioning chemotherapy regimen, which may include drugs like cyclophosphamide and fludarabine. This chemotherapy helps prepare the body to receive the CAR T-cells.
The dose of CAR T-cells can vary, but one study mentioned a target dose of 1 x 10⁶ cells per kg of body weight.
Efficacy
As MB-CART19.1 is still in clinical trials, its full efficacy is yet to be determined. However, the ongoing studies are designed to assess various efficacy measures, including:
- Overall response rate (ORR)
- Complete remission (CR) rate
- Minimal residual disease (MRD) response
- Duration of response
- Disease-free survival
- Overall survival
These outcomes will be evaluated at different time points, such as day 28, month 3, and up to 1 year after treatment.
Safety and Side Effects
As with any advanced therapy, MB-CART19.1 may cause side effects. Some potential side effects being monitored in clinical trials include:
- Cytokine Release Syndrome (CRS): A condition where the immune system becomes highly activated, potentially causing fever, low blood pressure, and other symptoms.
- CAR T-cell Associated Neurotoxicity Syndrome (ICANS): Neurological side effects that may occur after CAR T-cell therapy.
- Infections
- Leukopenia (low white blood cell count)
- Hypogammaglobulinemia (low antibody levels)
The severity of these side effects is being closely monitored in clinical trials.
Ongoing Research
Several clinical trials are currently underway to further investigate the safety and efficacy of MB-CART19.1 in various conditions:
- A phase I/II study in patients with relapsed or refractory CD19-positive B-cell malignancies, including ALL, NHL, and CLL.
- A study investigating its use in refractory or relapsed acute myeloid leukemia (AML) expressing CD19.
- A trial exploring its potential in treating autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and dermatomyositis/polymyositis.
These studies aim to determine the optimal dose, assess safety profiles, and evaluate the effectiveness of MB-CART19.1 in various patient populations.